(RTTNews) - Illumina, Inc. (ILMN), Tuesday said it has acquired Fluent BioSciences, developer of an emerging and highly differentiated single-cell technology.
"The addition of Fluent BioSciences to Illumina will provide significant and new capabilities to our customers in a key growth area and advances our multiomics growth strategy," said Steven Barnard, chief technology officer of Illumina. "Single-cell research opens doors to new areas of discovery, and Fluent's innovative, accessible, and flexible single-cell method will accelerate our ability to deliver full multiomics solutions for our customers."
Fluent's single-cell analysis technology eliminates the need for complex, expensive instrumentation and microfluidic consumables.
The acquisition closed on July 9, 2024, and has been funded with cash on hand.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
